Table 1.

Natural pharmaceutical products targeting BCSCs

Names	Target	Effects of a model	Ref.
Triterpene acid	C-MYC	Inhibits MDA-MB-231 stemness and the formation of mammospheres.	220
Gomisin M2	Wnt/β-catenin	Decreases the proliferation of TNBCs and mammosphere formation.	221
Honokiol	STAT3	Reduces of secondary transplanted tumors and the prolongation of metastasis time of MDA-MB-231 xenografts.	222
Apigenin	YAP/TAZ-TEAD	Inhibits TNBC stemness, migration, and tumor growth.	223
Andrographolide	Survivin	Inhibits the activity of human BCSCs in a dose-dependent manner and reduces the formation of mammospheres.	224
Ellagic acid	Actinin alpha 4 and β-catenin	Inhibits MDA-MB-231 and BT549 cell proliferation and prolongs the survival time of MMTV-PyMT mice.	225
8-Hydroxydaidzein	JAK2 and STAT3	Decreases BCSC characteristics and triggers apoptosis.	226
Sulforaphane	Wnt/β-catenin	Eliminates BCSCs and abrogates tumor growth.	227
Withaferin A	BMI-1	Attenuates BCSCs and inhibits breast tumor burden.	228
Benzyl isothiocyanate	Ron receptor tyrosine kinase	Inhibits the self-renewal ability of BCSCs.	229
Glabriden	TGF-β/SMAD2	Attenuates the breast CSC-like properties.	230
Isoliquiritigenin	DNA methyltransferase 1 (DNMT1)	Reduces the BCSC-like population and suppresses breast cancer initiation and progression.	231
Caffeic Acid Phenethyl Ester	CD44	Interfering with the growth of TNBC CSCs.	232